Human papillomavirus (HPV) infection leads to a spectrum of disease from genital warts to precancerous lesions to cervical and anal cancer and is a worldwide public health problem of epidemic proportions. Unique to HPV-related neoplasia, the presence of specific viral antigens such as the L1 capsid structural protein and the oncoproteins E6 and E7 provide opportunities for vaccine therapy.
**Human Papillomavirus Type 16 E7 Oncoprotein-induced Abnormal Centrosome Synthesis Is an Early Event in the Evolving Malignant Phenotype (CancerResearch)
http://cancerres.aacrjournals.org/cgi/content/full/61/6/2356
Most prophylactic vaccines are virus-like particles (VLP) composed of the L1 structural protein. Phase I trials have demonstrated safety and immunogenicity, but limited efficacy data are available. Therapeutic vaccine trials are reviewed including E6 and E7 vaccines comprised of peptides, fusion proteins, encapsulated plasmid DNA, and recombinant vaccinia virus
Since the vaccine does not contain any viral DNA, you cannot get infected with HPV by receiving this vaccine
Vaccine contains virus-like particles for HPV types 16 and 18, plus a substance called AS04, a novel proprietary adjuvant being developed by GSK Biologicals in collaboration with Corixa, that increases the immune system's response to a vaccine. GlaxoSmithKline announced in November 2004 that its vaccine, which contains two strains of HPV thought to cause 70 per cent of cervical cancers, had prevented 90 per cent of new infections and all persistent infections.
The US-based firm Merck announced similar results last week with its vaccine, which contains the same two cancer-causing HPV strains plus two strains that cause genital warts.
In 2004, the results from a phase II, randomised, double-blind clinical trial indicated that the vaccine may have clinical benefit to prevent HPV types 16 and 18.
